Related posts

Stocks fade, Bitcoin ETF false alarmMild reaction to Fed3 Best Cyclical and Value ETFs
BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

CRL provides drug discovery and safety testing services and is now trading at 22.6 times' Forward P/E (historical averages range from 19x to 33x). In the last five years, revenue growth was quite healthy, averaging around 12% on average, largely driven through acquisitions. The balance sheet is slightly leveraged, with net debt of $2.8B and net debt/EBITDA of around 2.7x. The company has been growing and repurchasing shares over the last few years. It is a solid company in our view, but as might be expected the valuation is a little expensive given the high quality of the business (not excessive though at 22X earnings).  Based on consensus estimates, sales are expected to grow by 2% this year and then normalize to around 7% over the next few years. Overall, an interesting name with strong growth and healthy cash generation. We would be comfortable owning it. 
Unlock Premium - Try 5i Free

0
BUY

Is undervalued and has been left behind because the market focused on Covid. CRL is in the same sector as Thermo Fisher, a sector that he likes. 

0
BUY
Trades at 20x PE. They draw from a strong demand from biopharma and boast strong free cash flow. Stay long.
0
BUY
Trades at 20x PE. They draw from a strong demand from biopharma and boast strong free cash flow. Stay long.
0
HOLD
Lost some gleam. Related to healthcare sector as a whole. Still confident in it. This is why you have a portfolio -- when some stocks fall, you have others to do the heavy lifting.
0
DON'T BUY
There have been few IPOs, but little biotech money has flowed into the market. This pressures CRL.
0
BUY ON WEAKNESS
Sensational, but it's a high-growth stock at a high price. It's profitable.
0
PAST TOP PICK
(A Top Pick May 30/19, Up 44%) A contract research organization who partners with major pharma companies for drug testing and clinical testing. This is the second company in this space that has done well for them. He would stick with it.
0
WAIT
It has had a great run and they consistently beat earnings expectations. He would be modestly concerned about their value metrics -- you are paying up right now. It has a 40 times PE ratio. He would wait until earnings are released.
0
TOP PICK
They are a contractor to pharma labs. A lot of large pharma companies outsource to them. They have predictable margins. They are growing organically and through acquisition. (Analysts’ price target is $148.13)
0
TOP PICK

Does safety testing, the efficacy, phase 1 through 3 trials for particular drugs for pharmaceutical companies. High growth, growing earnings last year at 17%.

0
Showing 1 to 11 of 11 entries
  • «
  • 1
  • »

Charles River Labs Intl(CRL-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Charles River Labs Intl is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Charles River Labs Intl(CRL-N) Frequently Asked Questions

What is Charles River Labs Intl stock symbol?

Charles River Labs Intl is a American stock, trading under the symbol CRL-N on the New York Stock Exchange (CRL). It is usually referred to as NYSE:CRL or CRL-N

Is Charles River Labs Intl a buy or a sell?

In the last year, 1 stock analyst published opinions about CRL-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Charles River Labs Intl.

Is Charles River Labs Intl a good investment or a top pick?

Charles River Labs Intl was recommended as a Top Pick by on . Read the latest stock experts ratings for Charles River Labs Intl.

Why is Charles River Labs Intl stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Charles River Labs Intl worth watching?

1 stock analyst on Stockchase covered Charles River Labs Intl In the last year. It is a trending stock that is worth watching.

What is Charles River Labs Intl stock price?

On 2024-05-29, Charles River Labs Intl (CRL-N) stock closed at a price of $211.48.